In8bio Correlations
INAB Stock | USD 0.28 0.01 3.45% |
The current 90-days correlation between In8bio Inc and Lantern Pharma is 0.01 (i.e., Significant diversification). The correlation of In8bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
In8bio Correlation With Market
Good diversification
The correlation between In8bio Inc and DJI is -0.18 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding In8bio Inc and DJI in the same portfolio, assuming nothing else is changed.
In8bio |
Moving against In8bio Stock
0.43 | FLGC | Flora Growth Corp | PairCorr |
0.38 | LLY | Eli Lilly | PairCorr |
0.37 | IMAB | I Mab | PairCorr |
0.36 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
0.33 | GNFT | Genfit | PairCorr |
0.32 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.32 | NUVL | Nuvalent | PairCorr |
0.41 | BNTX | BioNTech SE | PairCorr |
0.39 | ARDX | Ardelyx | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between In8bio Stock performing well and In8bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze In8bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
RVPH | 5.99 | 1.73 | 0.25 | (1.06) | 4.95 | 15.38 | 40.06 | |||
CUE | 7.78 | 1.28 | 0.18 | 2.85 | 6.18 | 20.27 | 67.78 | |||
LTRN | 3.61 | (0.18) | 0.00 | (0.02) | 0.00 | 9.58 | 28.68 | |||
GRCL | 5.71 | 1.33 | 0.18 | 1.37 | 6.35 | 16.34 | 52.11 | |||
ANIX | 2.51 | (0.22) | 0.00 | (0.26) | 0.00 | 4.64 | 31.27 | |||
INMB | 3.46 | (0.22) | 0.00 | 0.41 | 0.00 | 6.93 | 22.66 | |||
PYPD | 2.71 | (0.23) | 0.00 | 1.56 | 0.00 | 4.66 | 23.57 | |||
ZURA | 4.11 | (0.78) | 0.00 | (0.23) | 0.00 | 7.95 | 26.70 | |||
ANNX | 2.41 | (0.74) | 0.00 | (0.32) | 0.00 | 5.07 | 23.00 | |||
ICVX | 4.87 | 0.95 | 0.18 | 1.53 | 4.56 | 10.22 | 38.57 |
In8bio Corporate Management
Pharm MPH | VP Communications | Profile | |
TaiWei Ho | President, CoFounder | Profile | |
William Ho | President, CoFounder | Profile | |
Trishna MD | Chief Officer | Profile | |
Kate Rochlin | Chief Officer | Profile | |
Lawrence Lamb | CoFounder VP | Profile |